These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 34364779)

  • 1. Treatment patterns and outcomes before and after human regular U-500 insulin initiation via KwikPen® among US veterans with type 2 diabetes mellitus.
    Chen J; Borra S; Fan L; Huang A; Patel D; Juneja R
    J Diabetes Complications; 2021 Oct; 35(10):107995. PubMed ID: 34364779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns and Outcomes, Before and After Humulin R U-500 Initiation, Among High-Dose Type 2 Diabetes Mellitus Patients in the United States.
    Hood RC; Borra S; Fan L; Pollom RD; Huang A; Chen J
    Endocr Pract; 2021 Aug; 27(8):798-806. PubMed ID: 34089876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns and Outcomes Before and After Humulin R U-500 Initiation Among US Patients with Type 2 Diabetes Previously Prescribed ≤ 200 Units/day of U-100 Insulin.
    Chen J; Borra S; Huang A; Fan L; Pollom RD; Hood RC
    Diabetes Ther; 2022 Mar; 13(3):465-479. PubMed ID: 35190970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U500 regular insulin use in insulin-resistant type 2 diabetic veteran patients.
    Ziesmer AE; Kelly KC; Guerra PA; George KG; Dunn FL
    Endocr Pract; 2012; 18(1):34-8. PubMed ID: 21742613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance.
    Lane WS; Weinrib SL; Rappaport JM; Przestrzelski T
    Endocr Pract; 2010; 16(5):778-84. PubMed ID: 20350913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with U500 insulin: risks and benefits.
    Boldo A; Comi RJ
    Endocr Pract; 2012; 18(1):56-61. PubMed ID: 21803710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.
    Kabul S; Hood RC; Duan R; DeLozier AM; Settles J
    Health Qual Life Outcomes; 2016 Sep; 14(1):139. PubMed ID: 27716283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes.
    Luo J; Khan NF; Manetti T; Rose J; Kaloghlian A; Gadhe B; Jain SH; Gagne JJ; Kesselheim AS
    JAMA; 2019 Jan; 321(4):374-384. PubMed ID: 30694321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting.
    Davis SN; Wei W; Garg S
    Endocr Pract; 2011; 17(6):845-52. PubMed ID: 21550952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes.
    Lowery JB; Donihi AC; Korytkowski MT
    Diabetes Technol Ther; 2012 Jun; 14(6):505-7. PubMed ID: 22364143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
    Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
    Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective review of insulin requirements in patients using U-500 insulin hospitalized to a Veterans Affairs Hospital.
    Kedia R; Desouza C; Smith LM; Shivaswamy V
    J Diabetes Complications; 2017 May; 31(5):874-879. PubMed ID: 28274680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
    Lane W; Weinrib S; Rappaport J
    Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL.
    Hood RC; Arakaki RF; Wysham C; Li YG; Settles JA; Jackson JA
    Endocr Pract; 2015 Jul; 21(7):782-93. PubMed ID: 25813411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes.
    Lane WS; Weinrib SL; Rappaport JM; Hale CB; Farmer LK; Lane RS
    Endocr Pract; 2013; 19(2):196-201. PubMed ID: 23186973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Series of U-500 Insulin Use in Adults With Type 2 Diabetes and Severe Insulin Resistance.
    Zamora JM; Kong JM
    Can J Diabetes; 2021 Feb; 45(1):55-58. PubMed ID: 32847768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study.
    Grunberger G; Bhargava A; Ly T; Zisser H; Ilag LL; Malone J; Fan L; Zhang S; Johnson J
    Diabetes Obes Metab; 2020 Mar; 22(3):434-441. PubMed ID: 31865633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a Conservative Pharmacist-led U-500R Insulin Management Protocol in the Primary Care Setting.
    Dumont C; Fitzgerald L; Valdez CA
    J Prim Care Community Health; 2020; 11():2150132720973827. PubMed ID: 33218271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.